+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Pulmonary Drugs Market Research Report by Indication, Drug Class, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 248 Pages
  • October 2022
  • Region: Global
  • 360iResearch™
  • ID: 4829825
UP TO OFF until Dec 31st 2022
The Global Pulmonary Drugs Market size was estimated at USD 54.64 billion in 2021, USD 56.25 billion in 2022, and is projected to grow at a CAGR of 3.12% to reach USD 65.71 billion by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Pulmonary Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indication, the market was studied across Allergic Rhinitis, Asthma, COPD (Chronic Obstructive Pulmonary Disease), Cystic Fibrosis, Others, and Pulmonary Arterial Hypertension.
  • Based on Drug Class, the market was studied across Anti-cholinergic Agents, Anti-leukotrienes, Antihistamines, Beta-2 Agonists, Combination Drugs, Monoclonal Antibodies, Oral and Inhaled Corticosteroids, and Others.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Pulmonary Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Drugs Market, including AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., F.Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Mallinckrodt Pharmaceuticals, Merck & Co., Novartis International AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Inc.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Pulmonary Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Drugs Market?
6. What is the market share of the leading vendors in the Global Pulmonary Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Pulmonary Drugs Market?
Frequently Asked Questions about the Global Pulmonary Drugs Market

What is the estimated value of the Global Pulmonary Drugs Market?

The Global Pulmonary Drugs Market was estimated to be valued at $54.64 Billion in 2021.

What is the growth rate of the Global Pulmonary Drugs Market?

The growth rate of the Global Pulmonary Drugs Market is 3.1%, with an estimated value of $65.71 Billion by 2027.

What is the forecasted size of the Global Pulmonary Drugs Market?

The Global Pulmonary Drugs Market is estimated to be worth $65.71 Billion by 2027.

Who are the key companies in the Global Pulmonary Drugs Market?

Key companies in the Global Pulmonary Drugs Market include AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol, Myers Squibb Co., F.Hoffmann, La Roche Ltd., Gilead Sciences Inc. and Mallinckrodt Pharmaceuticals.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of chronic respiratory diseases, tobacco smoking
5.1.1.2. Drug innovation and availability of Biosimilars
5.1.1.3. Government and non-government initiatives
5.1.2. Restraints
5.1.2.1. Patent expiry of drugs
5.1.3. Opportunities
5.1.3.1. Increasing disposable income and rising investments in R&D
5.1.3.2. Increasing healthcare spending
5.1.3.3. Drug development through contract manufacturing
5.1.4. Challenges
5.1.4.1. Expensive clinical trials and commercialization of new drugs
5.2. Cumulative Impact of COVID-19
6. Pulmonary Drugs Market, by Indication
6.1. Introduction
6.2. Allergic Rhinitis
6.3. Asthma
6.4. COPD (Chronic Obstructive Pulmonary Disease)
6.5. Cystic Fibrosis
6.6. Others
6.7. Pulmonary Arterial Hypertension
7. Pulmonary Drugs Market, by Drug Class
7.1. Introduction
7.2. Anti-cholinergic Agents
7.3. Anti-leukotrienes
7.4. Antihistamines
7.5. Beta-2 Agonists
7.6. Combination Drugs
7.7. Monoclonal Antibodies
7.8. Oral and Inhaled Corticosteroids
7.9. Others
8. Americas Pulmonary Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Pulmonary Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Pulmonary Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AstraZeneca plc
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Bayer AG
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Boehringer Ingelheim GmbH
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Bristol-Myers Squibb Co.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. F.Hoffmann-La Roche Ltd.
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Gilead Sciences Inc.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. GlaxoSmithKline plc
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Mallinckrodt Pharmaceuticals
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Merck & Co.
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Novartis International AG
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Pfizer Inc.
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Sanofi S.A
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Teva Pharmaceutical Industries Ltd.
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Vertex Pharmaceuticals Inc
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL PULMONARY DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. GLOBAL PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL PULMONARY DRUGS MARKET DYNAMICS
FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2027
FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2027 (USD BILLION)
FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, 2018-2027 (USD BILLION)
FIGURE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE), 2018-2027 (USD BILLION)
FIGURE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, 2018-2027 (USD BILLION)
FIGURE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, 2018-2027 (USD BILLION)
FIGURE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, 2018-2027 (USD BILLION)
FIGURE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD BILLION)
FIGURE 22. GLOBAL PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG CLASS, 2027
FIGURE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, 2018-2027 (USD BILLION)
FIGURE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, 2018-2027 (USD BILLION)
FIGURE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2027 (USD BILLION)
FIGURE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2027 (USD BILLION)
FIGURE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2027 (USD BILLION)
FIGURE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD BILLION)
FIGURE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL AND INHALED CORTICOSTEROIDS, 2018-2027 (USD BILLION)
FIGURE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, 2018-2027 (USD BILLION)
FIGURE 31. AMERICAS PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 32. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 33. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 34. AMERICAS PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 35. ARGENTINA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 36. BRAZIL PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 37. CANADA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 38. MEXICO PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 39. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 40. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 41. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 42. UNITED STATES PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 43. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 44. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 45. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 46. ASIA-PACIFIC PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 47. AUSTRALIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 48. CHINA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 49. INDIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 50. INDONESIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 51. JAPAN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 52. MALAYSIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 53. PHILIPPINES PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 54. SINGAPORE PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 55. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 56. TAIWAN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 57. THAILAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 58. VIETNAM PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 63. DENMARK PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 64. EGYPT PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 65. FINLAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 66. FRANCE PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 67. GERMANY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 68. ISRAEL PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 69. ITALY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 70. NETHERLANDS PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 71. NIGERIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 72. NORWAY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 73. POLAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 74. QATAR PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 75. RUSSIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 76. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 77. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 78. SPAIN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 79. SWEDEN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 80. SWITZERLAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 81. TURKEY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 82. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 83. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 84. GLOBAL PULMONARY DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 85. GLOBAL PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 86. GLOBAL PULMONARY DRUGS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. GLOBAL PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2027 (USD BILLION)
TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2027 (USD BILLION)
TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2027 (USD BILLION)
TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2027 (USD BILLION)
TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, 2018-2027 (USD BILLION)
TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2027 (USD BILLION)
TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2027 (USD BILLION)
TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE), 2018-2027 (USD BILLION)
TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE), BY REGION, 2018-2027 (USD BILLION)
TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE), BY REGION, 2018-2027 (USD BILLION)
TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, 2018-2027 (USD BILLION)
TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2027 (USD BILLION)
TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2027 (USD BILLION)
TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, 2018-2027 (USD BILLION)
TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY REGION, 2018-2027 (USD BILLION)
TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY REGION, 2018-2027 (USD BILLION)
TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, 2018-2027 (USD BILLION)
TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2027 (USD BILLION)
TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2027 (USD BILLION)
TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, 2018-2027 (USD BILLION)
TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, 2018-2027 (USD BILLION)
TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2027 (USD BILLION)
TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2027 (USD BILLION)
TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2027 (USD BILLION)
TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2027 (USD BILLION)
TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2027 (USD BILLION)
TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2027 (USD BILLION)
TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2027 (USD BILLION)
TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2027 (USD BILLION)
TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2027 (USD BILLION)
TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2027 (USD BILLION)
TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD BILLION)
TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL AND INHALED CORTICOSTEROIDS, 2018-2027 (USD BILLION)
TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL AND INHALED CORTICOSTEROIDS, BY REGION, 2018-2027 (USD BILLION)
TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL AND INHALED CORTICOSTEROIDS, BY REGION, 2018-2027 (USD BILLION)
TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, 2018-2027 (USD BILLION)
TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY REGION, 2018-2027 (USD BILLION)
TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OTHERS, BY REGION, 2018-2027 (USD BILLION)
TABLE 50. AMERICAS PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 51. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 52. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 53. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 54. ARGENTINA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 55. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 56. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 57. BRAZIL PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 58. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 59. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 60. CANADA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 61. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 62. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 63. MEXICO PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 64. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 65. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 66. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 67. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2027 (USD BILLION)
TABLE 68. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 69. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 70. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 71. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 72. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 73. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 74. AUSTRALIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 75. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 76. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 77. CHINA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 78. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 79. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 80. INDIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 81. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 82. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 83. INDONESIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 84. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 85. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 86. JAPAN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 87. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 88. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 89. MALAYSIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 90. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 91. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 92. PHILIPPINES PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 93. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 94. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 95. SINGAPORE PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 96. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 97. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 98. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 99. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 100. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 101. TAIWAN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 102. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 103. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 104. THAILAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 105. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 106. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 107. VIETNAM PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 108. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 109. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 114. DENMARK PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 115. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 116. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 117. EGYPT PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 118. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 119. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 120. FINLAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 121. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 122. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 123. FRANCE PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 124. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 125. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 126. GERMANY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 127. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 128. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 129. ISRAEL PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 130. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 131. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 132. ITALY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 133. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 134. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 135. NETHERLANDS PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 136. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 137. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 138. NIGERIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 139. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 140. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 141. NORWAY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 142. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 143. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 144. POLAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 145. POLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 146. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 147. QATAR PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 148. QATAR PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 149. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 150. RUSSIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 151. RUSSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 152. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 153. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 154. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 155. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 156. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 157. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 158. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 159. SPAIN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 160. SPAIN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 161. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 162. SWEDEN PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 163. SWEDEN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 164. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 165. SWITZERLAND PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 166. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 167. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 168. TURKEY PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 169. TURKEY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 170. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 171. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 172. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 173. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 174. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 175. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2027 (USD BILLION)
TABLE 176. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD BILLION)
TABLE 177. GLOBAL PULMONARY DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 178. GLOBAL PULMONARY DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 179. GLOBAL PULMONARY DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 180. GLOBAL PULMONARY DRUGS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 181. GLOBAL PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 182. GLOBAL PULMONARY DRUGS MARKET MERGER & ACQUISITION
TABLE 183. GLOBAL PULMONARY DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 184. GLOBAL PULMONARY DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 185. GLOBAL PULMONARY DRUGS MARKET INVESTMENT & FUNDING
TABLE 186. GLOBAL PULMONARY DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 187. GLOBAL PULMONARY DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • F.Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Mallinckrodt Pharmaceuticals
  • Merck & Co.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc

Methodology

Loading
LOADING...